| Dino C. Miano |
Dino C. Miano is currently the Senior Vice President-CMC & Technical Operations at Avalo Therapeutics, Inc. He has an undergraduate degree from the University of Hartford and a doctorate degree from the University of Massachusetts. |
| Garry Arthur Neil |
Garry Arthur Neil founded Transcelerate Biopharma, Inc., where he worked as Chairman. Dr. Neil also currently works at Avalo Therapeutics, Inc., as Chairman, President & Chief Executive Officer from 2022, Manufacturers Association of Nigeria, as Vice Chairman, Celldex Therapeutics, Inc., as Independent Director from 2022, and various other companies. Dr. Neil also formerly worked at Arena Pharmaceuticals, Inc., as Chairman from 2021 to 2022, Pharmaceutical Research Corp., as Vice Chairman, Pharmaceutical Research & Manufacturers of America, as Chairman, and various other companies. Dr. Neil received his undergraduate degree from the University of Saskatchewan and doctorate degree from the University of Saskatchewan College of Medicine. |
| Lisa Hegg |
Lisa Hegg is currently working as the Senior VP-Infrastructure & Clinical Operation at Avalo Therapeutics, Inc. She previously worked as the VP-Development & Project Management at Aclaris Therapeutics, Inc. and as the VP, Head-Project, Planning & Management at GlaxoSmithKline LLC. Dr. Hegg holds a doctorate degree from Clark University and an undergraduate degree from Muhlenberg College. |
| Christopher Sullivan |
Christopher Sullivan is currently the Chief Financial Officer at Avalo Therapeutics, Inc. He previously worked as a Senior Manager at Ernst & Young LLP. Additionally, he served as a Controller at OpGen, Inc. from 2015 to 2017 and at Sucampo Pharmaceuticals LLC from 2017 to 2018. Mr. Sullivan completed his undergraduate degree at the University of Maryland. |
| Mitchell Chan |
Mitchell Chan is an Independent Director at Avalo Therapeutics, Inc. and a Director at Maryland Technology Council. He was previously a Director-Investor Relations at AstraZeneca PLC and the Chief Financial & Accounting Officer at Viela Bio, Inc. He holds an MBA from Rotman School of Management and undergraduate and graduate degrees from the University of Toronto. |
| Samantha Truex |
Samantha Truex is currently the Director at Artios Pharma Ltd. since 2022 and the Independent Director at Avalo Therapeutics, Inc. since 2024. Previously, she held positions such as Chief Executive Officer at Quench Bio, Inc. and Upstream Bio, Inc. She also served as a Director at HotSpot Therapeutics, Inc. and Vice President-Corporate Development at Biogen, Inc. from 2010 to 2014. Ms. Truex was the Chief Business Officer at Padlock Therapeutics, Inc. and the Chief Operating Officer at Synlogic Therapeutics from 2016 to 2017. She started her career as a Director at Sanofi from 1998 to 2006. Ms. Truex completed her undergraduate degree at Dartmouth College in 1992 and obtained an MBA from the Tuck School of Business at Dartmouth in 1995. She also holds an undergraduate degree from the Thayer School of Engineering At Dartmouth, which she received in 1993. |
| Aaron Kantoff |
Aaron Kantoff was the founder of Rayzebio, Inc. (founded in 2020) and Petrichor Scion Therapeutics Management LLC (founded in 2022) where he holds the titles of Director and General Partner respectively. He currently holds the position of Executive Director-Business Development at Braeburn Pharmaceuticals SPRL and is also a Director at Marengo Therapeutics, Inc., Silagene, Inc., Ceptur Therapeutics, Inc., Tourmaline Sub, Inc., Tourmaline Bio, Inc., and Avalo Therapeutics, Inc. In his former positions, Mr. Kantoff was a Director at Syntimmune, Inc. (2014-2018), Cure Forward Corp., Corvidia Therapeutics, Inc. (2016-2019), Marengo Therapeutics, Inc., Limelight Bio, Inc., Akero Therapeutics, Inc. (2018-2019), Centessa Pharmaceuticals Plc (2021-2022), and Medicxi Ventures (Jersey) Ltd. (2020-2021). He also worked as an Analyst at Rothschild, Inc. in 2009 and as a Vice President at Apple Tree Venture Management LLC (2013-2019). Mr. Kantoff obtained his undergraduate degree from The Leonard N Stern School of Business. |
| June Sherie Almenoff |
June Sherie Almenoff is currently an Independent Director at Tenax Therapeutics, Inc., an Independent Director at Avalo Therapeutics, Inc., and the Chief Medical Officer at RedHill Biopharma Ltd. She previously held positions as the President, CEO, Director & Chief Medical Officer at Furiex Pharmaceuticals, Inc., the Executive Chairman at RDD Pharma Ltd., an Independent Non-Executive Director at TiGenix NV, an Independent Director at Ohr Pharmaceutical, Inc., and a Director at Kurome Therapeutics, Inc. She is also a Member of the Infectious Diseases Society of America. Dr. Almenoff worked at GlaxoSmithKline LLC as the Vice President-Clinical Safety Organization from 1997 to 2010. She briefly served as the Chief Operating & Medical Officer at 9 Meters Biopharma, Inc. in 2018. Dr. Almenoff received her undergraduate degree from Smith College and her doctorate from the Icahn School of Medicine at Mount Sinai. |
| Gilla Kaplan |
Dr. Gilla Kaplan is an Independent Director at Avalo Therapeutics, Inc., an Independent Director at Tyra Biosciences, Inc., a Chairman at Desmond Tutu Hiv Foundation and a Venture Advisor at Israel Biotech Fund. She is on the Board of Directors at Avalo Therapeutics, Inc. and Tyra Biosciences, Inc. Dr. Kaplan was previously employed as a Director-Global Health Program by Bill & Melinda Gates Foundation Trust, a Professor by University of Medicine & Dentistry of New Jersey, an Assistant Director by Public Health Research Institute Center, an Independent Director by Celgene Corp., and an Associate Professor by The Rockefeller University. She also served on the board at MGI PHARMA, Inc. She received her undergraduate degree from The Hebrew University of Jerusalem, a graduate degree from the University of Tromso and a doctorate degree from the University of Tromso. |
| Jonathan H. Goldman |
Jonathan H. Goldman is currently the Chief Executive Officer at Clinical Ink, Inc. He is also a Director at Quadria Capital Investment Management Pte Ltd. and Astro Bidco Ltd. Additionally, he serves as an Independent Director at Avalo Therapeutics, Inc. Previously, Dr. Goldman held the position of Chief Executive Officer at Aptuit LLC. He was also a Director at Abzena Ltd. from 2018 to 2022. Prior to that, he served as the Chief Medical Officer & VP-Medical Affairs at POINT Biomedical Corp. and as an Operating Partner at Welsh, Carson, Anderson & Stowe. He also worked as an Associate Clinical Professor-Medicine at The University of California, San Francisco. Dr. Goldman's education includes an MBA from The Trustees of Columbia University in The City of New York. He also holds undergraduate and doctorate degrees from the University of London, as well as an MBA from the University of California, Berkeley. |
| Gunnar Magnus Modee Persson |
Gunnar Magnus Modee Persson is the founder of Aerocrine AB, which was founded in 1994. He currently holds multiple chairman positions at Cantargia AB, Attgeno AB, Galecto Biotech ApS, Karolinska Institutet Information AB, Initiator Pharma A, Hip Health Innovation Platform AB, Galecto Biotech AB, Eir Ventures Partners AB, Gyros AB, Avalo Therapeutics, Inc., Medical Prognosis Institute, Inc., Albumedix A, Mordin AB, Själbådan AB, Gyros Protein Technologies Holding AB, Perma Ventures AB, ADDI Medical AB, P O Persson. i Lidingö AB, Duomedix AB, Merigen AB, Sls Ventures AB, Avalo, Inc., and Karolinska Institutet. He has also held former positions as Chief Executive Officer of Karolinska Institutet Holding AB, Chief Executive Officer & Associate Professor of Caerus Consulting AS, Chairman of Scandinavian Life Science Ventures AB, Acting Chairman of Altimmune UK Ltd., Chairman of Karolinska Institutet Innovations AB, Chairman of Karolinska Institutet University Press AB, Chairman of Galecto, Inc., Chairman of Bioworks AB, Director of Ascendx Spine, Inc., Independent Director of Abliva AB, Director-Supervisory Board of Trigen Holdings AG, Director of Healthcap III Sidefund GP AB, Director of Lumavita AG, Director of KCIF Fund Management AB, Director of Medical Prognosis Institute A, Independent Director of Contera Pharma ApS, Independent Director of Karolinska Development AB, Independent Director of Mendus AB, Director of Bio-Works Technologies AB, Director of Karolinska Institutet Support AB, Director of Karolinska Institutet Housing AB, Director of Karolinska Institutet Science Park, Independent Director of Allarity Therapeutics A, Director of Addi Optioner AB, Partner of HealthCap AB, Principal of Odlander, Fredrikson & Co. AB, Gérant of Sanofi Winthrop, and Managing Partner of The Column Group LLC. He holds a doctorate degree from Karolinska Institutet. |
